Propolis Effects in Patients With Chronic Kidney Disease

University of Sao Paulo General Hospital

Status and phase: Completed; Phase 2

Conditions: Chronic Kidney Diseases

Treatments: Drug: Placebo; Drug: Propolis

Study type: Interventional

Funder types: Other

Identifiers

NCT02766036

USP Brazil (Other Identifier)

54326916.4.0000.0068

Details and patient eligibility

About

The aim of this study is to determine the impact of Propolis on proteinuria reduction and protection of the glomerular filtration rate in chronic renal failure patients.

Enrollment: 32 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• older than 18 years;
• less than 90 years;
• glomerular filtration rate between 25 and 70 ml / min;
• proteinuria in the urine 24 hours more than 300 mg or protein / creatinina in isolated urine greater than 0.3g / g or microalbuminuria (albumin / creatinine ratio) between 30-300 mg / g.

Exclusion criteria

• Pregnants;
• Neoplasia carrier;
• Renal transplant patients;
• Patients who refuse to participate in the study.
• Glomerulopathy on Immunosuppression

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

32 participants in 2 patient groups, including a placebo group

Propolis

Active Comparator group

Description:

Patients will continue to receive standard treatment for their comorbidities, determined by the attending physician. Patients will receive 500 mg / day of the propolis extract in the form of tablets split in two daily doses.

Treatment:

Drug: Propolis

Placebo

Placebo Comparator group

Description:

Patients will continue to receive standard treatment for their comorbidities, determined by the attending physician. Patients will receive 500 mg / day of the propolis-placebo in the form of tablets split in two daily doses.

Treatment:

Drug: Placebo